{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:10:58Z","timestamp":1785244258723,"version":"3.55.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin lymphoma. It is predominantly a disease of older individuals, with a median age at presentation of \u223c70 years. For the majority of patients, the management revolves around immuno-chemotherapy often followed by maintenance rituximab, and at relapse, a range of options are available. For the younger patient, it is possible to be more intensive with therapy, consolidate responses with high-dose procedures, and in a few there might be the prospect of a cure. The incorporation of high-dose cytarabine into the treatment algorithm has had a major impact on outcomes, with approximately half of the patients alive at 10 years whether an autologous stem cell transplant is adopted or not. Allogeneic transplantation produces some very durable responses in the relapsed setting and has a potential role up front in the highest-risk patients. However, with the advent of Bruton tyrosine kinase inhibitor and other highly effective nontraditional chemotherapeutic approaches, there is the potential for the management of this disease to change fundamentally over the next few years.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.419","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T11:05:27Z","timestamp":1480676727000},"page":"419-424","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Frontline therapy and role of high-dose consolidation in mantle cell lymphoma"],"prefix":"10.1182","volume":"2016","author":[{"given":"Simon","family":"Rule","sequence":"first","affiliation":[{"name":"Department of Haematology, Derriford Hospital, Plymouth and Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111704252478500_B1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjh.13796","article-title":"Rituximab plus hyper-CVAD alternating with MTX\/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center","volume":"172","author":"Chihara","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111704252478500_B2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2019111704252478500_B3","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2019111704252478500_B4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3324\/haematol.2015.128710","article-title":"The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial","volume":"101","author":"Rule","year":"2016","journal-title":"Haematologica"},{"key":"2019111704252478500_B5","first-page":"565","author":"Hermine","year":"2016"},{"issue":"3","key":"2019111704252478500_B6","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","article-title":"Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi","volume":"156","author":"Merli","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111704252478500_B7","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","article-title":"A phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213","volume":"24","author":"Bernstein","year":"2013","journal-title":"Ann Oncol"},{"issue":"3","key":"2019111704252478500_B8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"issue":"16","key":"2019111704252478500_B9","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111704252478500_B10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bbmt.2015.08.035","article-title":"Pretransplantation minimal residual disease predicts survival in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in complete remission","volume":"22","author":"Cowan","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"2019111704252478500_B11","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1182\/blood-2013-12-541953","article-title":"Nordic MCL-3 study: BEAM\/C conditioning intensified with 90Y-Ibritumomab-Tiuxetan in responding non-CR patients followed by autologous transplant in mantle cell lymphoma","volume":"123","author":"Kolstad","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019111704252478500_B12","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2013.088377","article-title":"First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group","volume":"98","author":"Arranz","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"2019111704252478500_B13","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/bjh.13773","article-title":"High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma","volume":"171","author":"Cassaday","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111704252478500_B14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bjh.13929","article-title":"A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma","volume":"173","author":"Armand","year":"2016","journal-title":"Br J Haematol"},{"issue":"23","key":"2019111704252478500_B15","first-page":"Abstract 126","article-title":"Pre-transplant R-bendamustine induces high rates of minimal residual disease in MCL patients: updated results of S1106: US intergroup study of a randomised phase II trial of R-HCVAD vs. R-bendamustine followed by autologous stem cell transplants for patients with mantle cell lymphoma [abstract]. Blood","volume":"126","author":"Chen","year":"2015","journal-title":"."},{"key":"2019111704252478500_B16","first-page":"Abstract 146","author":"Le Gouill","year":"2014"},{"issue":"26","key":"2019111704252478500_B17","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111704252478500_B18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","article-title":"Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality","volume":"32","author":"Fenske","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111704252478500_B19","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00277-014-2087-z","article-title":"Allogeneic stem cell transplantation for mantle cell lymphoma--final report from the prospective trials of the East German Study Group Haematology\/Oncology (OSHO)","volume":"93","author":"Kr\u00fcger","year":"2014","journal-title":"Ann Hematol"},{"key":"2019111704252478500_B20","first-page":"Abstract 19","article-title":"Reduced intensity conditioned allogeneic stem cell transplantation (RIC-allo) as front-line therapy for mantle cell lymphoma (MCL): results from the UK phase II mini allo study (CRUK: C7627\/A9080)","volume":"173","author":"Tucker","year":"2016","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111704252478500_B21","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111704252478500_B22","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"issue":"9873","key":"2019111704252478500_B23","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"19","key":"2019111704252478500_B24","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Open-label, randomized, noninferiority study of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of advanced indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2019111704252478500_B25","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"Visco","year":"2013","journal-title":"J Clin Oncol"},{"key":"2019111704252478500_B26","first-page":"130","article-title":"Rituximab, bendamustine and cytarabine (RBAC500) as induction therapy in elderly patients with mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi","volume":"33","author":"Visco","year":"2015","journal-title":"Hematol Oncol"},{"issue":"1","key":"2019111704252478500_B27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","article-title":"Mantle cell lymphoma: evolving management strategies","volume":"125","author":"Campo","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111704252478500_B28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2141.2010.08315.x","article-title":"Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma","volume":"151","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111704252478500_B29","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2141.2011.08820.x","article-title":"VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study","volume":"155","author":"Chang","year":"2011","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111704252478500_B30","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2013-08-523845","article-title":"Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)","volume":"123","author":"Chang","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111704252478500_B31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/bjh.13818","article-title":"Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601","volume":"172","author":"Till","year":"2016","journal-title":"Br J Haematol"},{"issue":"23","key":"2019111704252478500_B32","first-page":"Abstract 339","article-title":"Bortezomib maintenance therapy after induction with R-CHOP, ARA-C and autologous stem cell transplantation in newly diagnosed MCL patients, results of a multicenter phase II HOVON study [abstract]. Blood","volume":"126","author":"Doorduijn","year":"2015","journal-title":"."},{"issue":"10","key":"2019111704252478500_B33","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111704252478500_B34","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N Engl J Med"},{"key":"2019111704252478500_B35","author":"Albertsson-Lindblad"},{"issue":"6","key":"2019111704252478500_B36","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111704252478500_B37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"2019111704252478500_B38","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111704252478500_B39","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111704252478500_B40","first-page":"Abstract 254","article-title":"A phase 1 study of Venetoclax (ABT-199\/GDC - 0199) monotherapy in patients with relapsed\/refractory non-Hodgkin lymphoma [abstract]. Blood","volume":"126","author":"Gerecitano","year":"2015","journal-title":"."}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/419\/1251170\/hem088373.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/419\/1251170\/hem088373.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T04:25:33Z","timestamp":1573964733000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/419\/21125\/Frontline-therapy-and-role-of-highdose"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.419","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}